193 related articles for article (PubMed ID: 19690195)
1. Imaging mass spectrometry of a specific fragment of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 2 discriminates cancer from uninvolved prostate tissue.
Cazares LH; Troyer D; Mendrinos S; Lance RA; Nyalwidhe JO; Beydoun HA; Clements MA; Drake RR; Semmes OJ
Clin Cancer Res; 2009 Sep; 15(17):5541-51. PubMed ID: 19690195
[TBL] [Abstract][Full Text] [Related]
2. The use of matrix coating assisted by an electric field (MCAEF) to enhance mass spectrometric imaging of human prostate cancer biomarkers.
Wang X; Han J; Hardie DB; Yang J; Borchers CH
J Mass Spectrom; 2016 Jan; 51(1):86-95. PubMed ID: 26757076
[TBL] [Abstract][Full Text] [Related]
3. Zonal regulation of collagen-type proteins and posttranslational modifications in prostatic benign and cancer tissues by imaging mass spectrometry.
Angel PM; Spruill L; Jefferson M; Bethard JR; Ball LE; Hughes-Halbert C; Drake RR
Prostate; 2020 Sep; 80(13):1071-1086. PubMed ID: 32687633
[TBL] [Abstract][Full Text] [Related]
4. Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry.
Cazares LH; Adam BL; Ward MD; Nasim S; Schellhammer PF; Semmes OJ; Wright GL
Clin Cancer Res; 2002 Aug; 8(8):2541-52. PubMed ID: 12171882
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer diagnosis and characterization with mass spectrometry imaging.
Kurreck A; Vandergrift LA; Fuss TL; Habbel P; Agar NYR; Cheng LL
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):297-305. PubMed ID: 29209003
[TBL] [Abstract][Full Text] [Related]
6. MALDI-MS tissue imaging identification of biliverdin reductase B overexpression in prostate cancer.
Pallua JD; Schaefer G; Seifarth C; Becker M; Meding S; Rauser S; Walch A; Handler M; Netzer M; Popovscaia M; Osl M; Baumgartner C; Lindner H; Kremser L; Sarg B; Bartsch G; Huck CW; Bonn GK; Klocker H
J Proteomics; 2013 Oct; 91():500-14. PubMed ID: 23954705
[TBL] [Abstract][Full Text] [Related]
7. Identification of clinically relevant protein targets in prostate cancer with 2D-DIGE coupled mass spectrometry and systems biology network platform.
Ummanni R; Mundt F; Pospisil H; Venz S; Scharf C; Barett C; Fälth M; Köllermann J; Walther R; Schlomm T; Sauter G; Bokemeyer C; Sültmann H; Schuppert A; Brümmendorf TH; Balabanov S
PLoS One; 2011 Feb; 6(2):e16833. PubMed ID: 21347291
[TBL] [Abstract][Full Text] [Related]
8. MALDI MS profiling of post-DRE urine samples highlights the potential of β-microseminoprotein as a marker for prostatic diseases.
Flatley B; Wilmott KG; Malone P; Cramer R
Prostate; 2014 Jan; 74(1):103-11. PubMed ID: 24115268
[TBL] [Abstract][Full Text] [Related]
9. The expression profile of phosphatidylinositol in high spatial resolution imaging mass spectrometry as a potential biomarker for prostate cancer.
Goto T; Terada N; Inoue T; Nakayama K; Okada Y; Yoshikawa T; Miyazaki Y; Uegaki M; Sumiyoshi S; Kobayashi T; Kamba T; Yoshimura K; Ogawa O
PLoS One; 2014; 9(2):e90242. PubMed ID: 24587297
[TBL] [Abstract][Full Text] [Related]
10. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men.
Adam BL; Qu Y; Davis JW; Ward MD; Clements MA; Cazares LH; Semmes OJ; Schellhammer PF; Yasui Y; Feng Z; Wright GL
Cancer Res; 2002 Jul; 62(13):3609-14. PubMed ID: 12097261
[TBL] [Abstract][Full Text] [Related]
11. MALDI tissue imaging: from biomarker discovery to clinical applications.
Cazares LH; Troyer DA; Wang B; Drake RR; Semmes OJ
Anal Bioanal Chem; 2011 Jul; 401(1):17-27. PubMed ID: 21541816
[TBL] [Abstract][Full Text] [Related]
12. Prostate carcinoma tissue proteomics for biomarker discovery.
Zheng Y; Xu Y; Ye B; Lei J; Weinstein MH; O'Leary MP; Richie JP; Mok SC; Liu BC
Cancer; 2003 Dec; 98(12):2576-82. PubMed ID: 14669276
[TBL] [Abstract][Full Text] [Related]
13. Differentiating tumor heterogeneity in formalin-fixed paraffin-embedded (FFPE) prostate adenocarcinoma tissues using principal component analysis of matrix-assisted laser desorption/ionization imaging mass spectral data.
Panderi I; Yakirevich E; Papagerakis S; Noble L; Lombardo K; Pantazatos D
Rapid Commun Mass Spectrom; 2017 Jan; 31(2):160-170. PubMed ID: 27791282
[TBL] [Abstract][Full Text] [Related]
14. [Proteomic analysis of prostate cancer using surface enhanced laser desorption/ionization mass spectrometry].
Pan YZ; Xiao XY; Zhao D; Zhang L; Ji GY; Li Y; He DC; Zhao XJ; Yang BX
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(45):3172-5. PubMed ID: 16405834
[TBL] [Abstract][Full Text] [Related]
15. Glycoproteomic analysis of prostate cancer tissues by SWATH mass spectrometry discovers N-acylethanolamine acid amidase and protein tyrosine kinase 7 as signatures for tumor aggressiveness.
Liu Y; Chen J; Sethi A; Li QK; Chen L; Collins B; Gillet LC; Wollscheid B; Zhang H; Aebersold R
Mol Cell Proteomics; 2014 Jul; 13(7):1753-68. PubMed ID: 24741114
[TBL] [Abstract][Full Text] [Related]
16. Classification of HER2 receptor status in breast cancer tissues by MALDI imaging mass spectrometry.
Rauser S; Marquardt C; Balluff B; Deininger SO; Albers C; Belau E; Hartmer R; Suckau D; Specht K; Ebert MP; Schmitt M; Aubele M; Höfler H; Walch A
J Proteome Res; 2010 Apr; 9(4):1854-63. PubMed ID: 20170166
[TBL] [Abstract][Full Text] [Related]
17. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients.
Qu Y; Adam BL; Yasui Y; Ward MD; Cazares LH; Schellhammer PF; Feng Z; Semmes OJ; Wright GL
Clin Chem; 2002 Oct; 48(10):1835-43. PubMed ID: 12324514
[TBL] [Abstract][Full Text] [Related]
18. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
[TBL] [Abstract][Full Text] [Related]
19. The transcription factor FOXF1 promotes prostate cancer by stimulating the mitogen-activated protein kinase ERK5.
Fulford L; Milewski D; Ustiyan V; Ravishankar N; Cai Y; Le T; Masineni S; Kasper S; Aronow B; Kalinichenko VV; Kalin TV
Sci Signal; 2016 May; 9(427):ra48. PubMed ID: 27165781
[TBL] [Abstract][Full Text] [Related]
20. Multivariate analyses for biomarkers hunting and validation through on-tissue bottom-up or in-source decay in MALDI-MSI: application to prostate cancer.
Bonnel D; Longuespee R; Franck J; Roudbaraki M; Gosset P; Day R; Salzet M; Fournier I
Anal Bioanal Chem; 2011 Jul; 401(1):149-65. PubMed ID: 21519967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
